Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.42 |
| ▸ | PDE1A | P54750 | 3/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291345 | 0.89 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6288579 | 0.88 | PDE2A (0.45) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6288598 | 0.84 | PDE2A (0.46) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6291877 | 0.81 | CRHR1 (0.42) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6288549 | 0.79 | PDE5A (0.54) | PDE5APDE1APDE1BPDE1CTNKS | |
| SCHEMBL5884423 | 0.78 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6288563 | 0.76 | ATM (0.47) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6291830 | 0.73 | PDE2A (0.45) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL6291287 | 0.71 | PDE2A (0.47) | PDE2A | |
| SCHEMBL6288512 | 0.71 | CRHR1 (0.46) | PDE5APDE1APDE1BPDE1CPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936609-B2 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1404677-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000693-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | PDE3A, PDE2A, PDE4A | PDE5A 4/4885PDE1A 8/4885PDE1B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.